Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page
- Check4 days agoChange DetectedThe deletions remove a 403 Forbidden page and the Home link from the study details view, removing the error content and the associated navigation element.SummaryDifference0.5%

- Check11 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the study details and navigation with a standard error screen, indicating access to the record is currently blocked.SummaryDifference18%

- Check18 days agoChange DetectedThe study record now marks the trial as Completed and lists actual start and completion dates (2016-02-16 start; 2026-09-04 completion), replacing the previous Active, not recruiting status and estimates.SummaryDifference0.6%

- Check32 days agoChange DetectedUpdated the page revision from v3.6.5 to v3.6.6, indicating a minor metadata update to the study record. This change appears to be limited to the revision tag and does not modify core study details such as eligibility, endpoints, or contacts.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page revision label was updated from v3.6.4 to v3.6.5, indicating a small backend or content update. No study details or functionality were changed.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page now shows Revision: v3.6.4 in place of v3.6.3, indicating a small update to the page version. This does not modify study details or other user-facing content.SummaryDifference0.1%

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.